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ORIGINAL ARTICLE
Background/Aims: No definite conclusions have been reached about the natural history of patients with isolated
microscopic hematuria (IMH). In this study, we observed the natural history of patients with IMH and examined
factors related to a pathologic diagnosis and subsequent prognosis. 
Methods: We retrospectively evaluated 156 subjects with IMH who had a renal biopsy performed. Of the 156
subjects, 33.3% were diagnosed with IgA nephropathy, 23.7% with mesangial proliferative glomerulonephritis,
15.4% with glomerular minor lesion, and 12.8% with thin basement membrane nephropathy; 6.4% had normal
biopsies.
Results: We followed up with 100 subjects for about 31 months. During this follow-up period, two subjects who had
received a pathologic diagnosis of IgA nephropathy developed chronic kidney disease. During the course of the
study, one of these subjects presented with proteinuria and hypertension and the other with proteinuria. The
overall incidences of proteinuria and hypertension were 6% and 5% respectively.
Conclusions: The prognosis for patients with IMH was relatively favorable, but patients developing proteinuria
and/or hypertension require careful observation and management during the follow-up period. (Korean J Intern
Med 2009;24:356-361)
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INTRODUCTION
Isolated microscopic hematuria (IMH) is a common
urinary abnormality in clinical practice [1-4]. IMH is
defined as persistent asymptomatic microscopic hematuria
without hypertension, proteinuria, renal insufficiency,
urinary tract infection, or structural abnormality of the
urinary tract, and may it be an early sign of glomeru-
lonephritis [3-7]. No definite conclusions have been
reached regarding the natural history of patients with
IMH. Until recently, a prognosis of IMH was considered
benign, but new studies have revealed that some patients
have a poor outcome, particularly those who developed
proteinuria and/or hypertension during the follow-up
period [8-11]. The decision to perform a renal biopsy on a
patient with IMH also remains controversial. Some
nephrologists do not recommend a renal biopsy because
identification of a specific disease will not make any
difference to either patient management or treatment
outcome; other nephrologists recommend a renal biopsy
because they think it can provide a more accurate diagnosis
and prognosis [12,13]. In this study, we retrospectively
reviewed data about 156 patients with IMH who had
undergone a percutaneous renal biopsy to observe the
natural history of patients with IMH and to examine
factors related to pathologic diagnosis and prognosis.Kim BS, et al. Renal pathology in patients with IMH    357
METHODS
Subjects
This study was retrospective and was conducted in
accordance with the principles of the 1983 Helsinki
Declaration. Potential subjects were patients who had
been diagnosed with IMH and had undergone a percu-
taneous renal biopsy between June 2002 and August
2007. We reviewed the medical history and data of these
patients at initial presentation. Patients were included in
the study if they had persistent hematuria (red blood cell
per high-power field in urinary sediment >5 on three or
more occasions over 4 or more weeks, and sterile urine in
a routine culture), serum creatinine <1.2 mg/dL, a urine
protein to creatinine ratio <0.3 g/mg, resting systolic
blood pressure <40 mmHg, and diastolic blood pressure
<90 mmHg. We excluded patients who had a history of
edema or gross hematuria or who were younger than 15
years. Computed tomography, abdomen sonography,
and/or urine cytology were performed for all subjects, and
we excluded patients with stones, malignancy, trauma,
and/or tuberculosis in the urinary tract. We also excluded
patients with any systemic disease or a family history
suggestive of Alport’s syndrome. A total of 156 subjects
were enrolled in the study. In all subjects, the amount of
proteinuria was measured by determining the urine
protein-to-creatinine ratio. The glomerular filtration rate
(GFR) was calculated using the Modification of Diet in
Renal Disease (MDRD) equation. Renal biopsy specimens
were examined by a renal pathologist using light microscopy,
indirect immunofluorescence, and electric microscopy.
The pathologic diagnosis was conducted according to
WHO criteria for renal disease classification [14]. Of the
156 subjects, 100 were monitored through follow-up
appointments for at least one year. These follow-up
appointments also included testing for clinical parameters
associated with hematuria, GFR, proteinuria, and
hypertension. Chronic kidney disease (CKD) was defined
as an estimated GFR <60 mL/minute/1.73 m
2 for 3
months or more. All parameters were recorded at each
clinic visit.
Statistical analysis
All results are expressed as mean±standard deviation.
Data were compared using Student’s t-test, the χ
2 test, or
Fisher’s test, as appropriate. The Kaplan-Meier method
with a log rank test was used to compare the cumulative
incidence of survival free of CKD, proteinuria, and hyper-
tension. The Cox proportional hazard model was used
to determine an independent factor for risk of CKD,
proteinuria, and hypertension. Variables included (at
presentation) age, gender, body mass index, mean arterial
pressure, degree of proteinuria, serum creatinine level,
and pathology of the renal biopsy. A p values of <0.05
were considered significant. All statistical analyses were




Table 1 list clinical characteristics for the 156 subjects
with IMH at the time of the renal biopsy. Subjects had
Table 2. Renal pathologic diagnosis
Renal histological finding No. of patients (%)
IgA nephropathy 52 (33.3)
MsPGN 37 (23.7)
Glomerular minor lesion 24 (15.4)
TBMN 20 (12.8)




MsPGN, mesangial proliferative glomerulonephritis; TBMN, thin
basement membrane nephropathy; FSGS, focal segmental
glomerulosclerosis; MGN, membranous glomerulonephritis; MPGN,
membranoproliferative glomerulonephritis.




Urine protein to creatinine ratio 0.09±0.06
Serum creatinine, mg/dL 0.79±0.15
Mean GFR, mL/min/1.73 m
2 101±21.3
Systolic blood pressure, mmHg 106±11.3
Diastolic blood pressure, mmHg 67±8.3
Body mass index, kg/m
2 23.1±3.2
Total cholesterol, mg/dL 173.0±31.6
Values are mean±SD.
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a mean age of 38.3±11.9 years and included 50 males and
106 females. Mean systolic blood pressure was 106±11.3
mmHg, and mean diastolic blood pressure was 67±8.3
mmHg. Mean serum creatinine concentration was 0.79±
0.15 mg/dL, and mean estimated GFR was 101±21.3
mL/minute/1.73 m
2, according to the abbreviated MDRD
study equation. Mean urine protein-to-creatinine ratio
was 0.09±0.06 g/mg. 
Table 2 lists the pathologic diagnoses for the 156
subjects with IMH. The most frequent diagnosis was IgA
nephropathy (52 subjects, 33.3%). Subclasses of the Haas
classification were distributed heterogeneously. Mesangial
proliferative glomerulonephritis (MsPGN) was observed
in 37 subjects (23.7%), minimal mesangiopathy in 24
subjects (15.4%), and thin basement membrane
nephropathy (TBMN) in 20 subjects (12.8%). Ten subjects
(6.4%) had a normal biopsy, eight (5.1%) had focal
segmental glomerulosclerosis (FSGS), three (1.9%) had
membranous glomerulonephritis (MGN), and two (1.3%)
had membranoproliferative glomeruolonephritis (MPGN).
Clinical course
Of the 156 subjects, 100 were monitored through follow-
up appointments for at least 1 year. These 100 subjects
included 22 males and 78 females with a mean age of
35.9±11.4. The mean follow-up duration from renal biopsy
to the last outpatient check-up was 31.6±14.1 months. A
comparison of clinical data from all 156 subjects and the
subset of 100 subjects revealed no statistical differences.
Table 3 lists the clinical findings for the 100 subjects who
participated from the renal biopsy through to the end of
the follow-up period. Mean systolic blood pressure
increased significantly (p<0.001) through this follow-up
period, but no significant changes appeared in mean
diastolic pressure, mean urine protein-to-creatinine ratio,
mean serum creatinine concentration, or mean GFR
between the time of initial presentation and the end of
the follow-up period. Table 4 lists the characteristics of
subjects who developed CKD, proteinuria, and hyper-
tension during the follow-up period. By the end of the
follow-up period, two subjects (2%) had developed CKD.
No subjects had reached end-stage renal disease by this
point. Two subjects developed CKD during the follow-up
period; one of these developed proteinuria and hypertension,
and the other developed only proteinuria. Pathologic
diagnoses of the two subjects who developed CKD revealed
IgA nephropathy. During the follow-up period, proteinuria
Table 3. Comparison of clinical data in 100 patients
with isolated microscopic hematuria during the follow-
up period
At renal biopsy At the end of 
follow-up
Systolic blood pressure, mmHg 105.3±13.4 112.7±11.3
Diastolic blood pressure, mmHg 67.4±6.7 67.7±8.1
Urine protein to creatinine ratio 0.09±0.07 0.12±0.14
Serum creatinine, mg/dL 0.78±0.15 0.77±0.17
Mean GFR, mL/min/1.73 m
2 98.6±21.5 100.7±24.3
Adverse renal events
Chronic kidney disease 0 2 (2)
Proteinuria 0 6 (6)
Hypertension 0 5 (5)
Values are mean±SD or frequency (%).
GFR, glomerular filtration rate.
Table 4. Clinical characteristics of 10 patients with adverse renal events
Case Age Sex Pathologic diagnosis Adverse renal event
1 47 Female FSGS Proteinuria
2 45 Female IgA nephropathy III Proteinuria
3 46 Female Glomerular minor lesion Proteinuria
4 43 Female MsPGN Proteinuria
5 19 Male TBMN Hypertension
6 49 Female FSGS Hypertension
7 19 Male IgA nephropathy II Hypertension
8 37 Female IgA nephropathy II Hypertension
9 19 Female IgA nephropathy II Proteinuria, CKD
10 50 Female IgA nephropathy II Proteinuria, hypertension, CKD
FSGS, focal segmental glomerulosclerosis; IgA nephropathy, immunoglobulin A nephropathy; MsPGN, mesangial proliferative glomerulonephritis;
TBMN, thin basement membrane nephropathy; CKD, chronic kidney disease.Kim BS, et al. Renal pathology in patients with IMH    359
appeared in six subjects (6%). The histological findings for
these subjects were IgA nephropathy (three cases), FSGS
(one case), MsPGN (one case), and minimal mesangiopathy
(one case). Two of the six subjects who presented with
proteinuria progressed to CKD. During the follow-up
period, hypertension appeared in five subjects (5%). The
pathologic diagnoses of these subjects were IgA
nephropathy (three cases), FSGS (one case), and TBMN
(one case). One of the five subjects who presented with
hypertension progressed to CKD. During the follow-up
period, microscopic hematuria disappeared in four subjects
(4%), and the pathologic diagnosis for all these patients
was IgA nephropathy. None of these subjects presented
with CKD, proteinuria, or hypertension during the follow-
up period. 
We used a multivariate model (Cox proportional hazard
model) to determine the independent risk factor for
adverse renal events (CKD, proteinuria, or hypertension).
We were unable to find a useful clinical parameter from
data at presentation including age, gender, body mass
index, mean arterial pressure, the degree of proteinuria,
serum creatinine level, and pathology of the renal biopsy.
DISCUSSION
In this study, we investigated the pathologic diagnosis
of 156 patients with IMH and the natural history of 100
of these patients who were monitored through follow-up
appointments for a mean duration of about 36 months.
Subjects with IMH had various diagnoses. The most
common cause of IMH was glomerulonephritis, especially
IgA nephropathy. The prevalences of IgA nephropathy
and TBMN were 33.3% and 12.8% respectively, similar to
previous reports [1-6]. Previous studies have reported that
IgA nephropathy and TBMN are present in 10-60% of
patients with IMH. Interestingly, the prevalence rate of
IgA nephropathy and TBMN differed by geographic
location because the frequency of urinalysis screening,
indications for renal biopsy in patients with IMH, and
availability of electron microscopy differs among countries
[13-18]. We also documented the presence of relatively
severe pathologic types, such as FSGS, MGN, and MPGN,
in a number of cases, implying a clinico-pathological
disassociation. Some, but not all, previous studies have
also reported the presence of relatively severe pathologic
types in subjects with IMH. This finding might be related
to the number of subjects enrolled in the studies. Therefore,
renal biopsy in patients with IMH might provide a more
accurate diagnosis and also yield prognostic indicators
including interstitial fibrosis and tubular atrophy [19,20].
No definitive prognosis is available for patients with
IMH. Many previous studies have reported that the
prognosis for patients with IMH is good, but some recent
studies have reported poor outcomes. In particular, they
found that subjects who developed proteinuria during
the study, as well as subjects with developmental hyper-
tension during the follow-up period, were more liable to
have renal function deterioration than were those who
had been diagnosed with proteinuria at the beginning of
the study [8-11]. Of our subjects, two (2%) developed CKD
during the mean 36 months of follow-up; the pathologic
diagnoses for these subjects were both IgA nephropathy.
The incidence of proteinuria and hypertension were 6%
and 5% respectively during the follow-up period. Our data
support that the prognosis of patients with IMH is not
benign, and IMH might gradually progress to proteinuria
and/or hypertension with time. One of the two subjects
who developed CKD also developed proteinuria and
hypertension during the follow-up period, whereas the
other developed only proteinuria. Our data might also
indicate that the development of proteinuria and/or
hypertension during the follow-up period is a risk factor
for progression to CKD in patients with IMH. Therefore,
careful long-term follow-up and early detection of patients
who show progression is important, and strategies for
treatment should be designed early for these patients in
an attempt to prevent CKD [4]. We found that during the
follow-up period, hematuria disappeared in some subjects
with asymptomatic persistent hematuria. Coppo and
D’Amico [21]. also reported spontaneous remission or
complete recovery 5-30% of adult patients with IgA
nephropathy over a long-term follow-up period. In this
study, hematuria disappeared in 4% of all subjects. The
pathologic diagnoses for these subjects all included IgA
nephropathy, and none developed CKD, proteinuria, or
hypertension during the follow-up period. However, it is
not clear whether clinical remission represents pathological
remission. Alarmartine et al. [22] conducted repeated
renal biopsies on patients with primary IgA nephropathy
and did not observe pathological remission even in a
patient with complete clinical remission. Therefore,
careful long-term follow-up might be needed even for
patients with IgA nephropathy whose hematuria disappears
during the follow-up period. 
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tomatic persistent microscopic hematuria are still poorly
defined. IMH seems to be a specific indication for a renal
biopsy only among a minority of nephrologists; most
nephrologists consider the prognosis for patients with
IMH to be good and think that a renal biopsy will not
affect treatment management or outcome [12,13]. However,
Shu et al. highlighted the importance of performing a
renal biopsy on IMH patients because minimal urinary
abnormality with normal renal function at presentation
does not necessarily imply a favorable outcome in certain
patients; in addition, tubular atrophy and interstitial
fibrosis, but not glomerular change, correlate with a worse
prognosis [23]. Sparwasser et al. [24] suggested that a
kidney biopsy be considered optional, and that once a
diagnosis is established, repeated and unnecessary
examinations can be avoided in young patients with
persistent hematuria. Shen et al. [4] suggested that the
urinary albumin/creatinine ratio, serum IgA level, and
serum IgA/C3 ratio can serve as non-invasive markers to
predict the necessity of a renal biopsy in adult patients
with IMH. In this study, clinical findings at presentation
were not helpful in differential diagnoses of patients with
IMH. Renal biopsies provided a diagnosis for most IMH
subjects and helped minimize unnecessary further investi-
gation of their hematuria. Early pathologic diagnosis of
patients with IMH helped to distinguish those with major
glomerulonephritis, who had worse long-term prognoses
than those with TBMN or a normal biopsy. These diagnoses
enabled careful follow-up and consideration of early
therapeutic strategies. However, renal biopsy results did
not alter the management of patients with IMH at the
time of presentation. Furthermore, it is not clear whether
early diagnosis of IgA nephropathy has a prognostic
impact, as these results can only be obtained after careful
long-term follow-up. A renal biopsy is an invasive and
costly procedure [25], although in our study the procedure
did not result in major complications. Therefore, a renal
biopsy may be optional for patients with IMH and
indicators such as microalbumiuria may be a useful tool to
aid in decisions about whether to proceed with a renal
biopsy. 
In conclusion, we found that glomerulonephritis was
the major cause of IMH. The prognosis for patients with
IMH may be favorable. However, careful observation and
management are required for patients who develop
proteinuria and/or hypertension during the follow-up
period. A renal biopsy may be optional in consideration of
its benefits and risk.
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